A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

• ClinicalTrials.gov Identifier: NCT06159725
• Recruitment Status: Recruiting
• First Posted: December 7, 2023
• Last Update Posted: May 9, 2024
• Sponsor: Clarametyx Biosciences, Inc.
• Information provided by (Responsible Party): Clarametyx Biosciences, Inc.

Study Description

Brief Summary:

CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF).

The main questions the study aims to answer are:

• Are single doses of CMTX-101 IV infusion safe and tolerated
• What is the pharmacokinetic (PK) profile of single doses of CMTX-101
• Do single doses of CMTX-101 induce development of anti-drug antibodies (ADA) and neutralizing antibodies (Nabs)

Condition or disease	Intervention/treatment	Phase
Persistent Infection; Cystic Fibrosis	Drug: CMTX-101; Drug: Placebo	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 41 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Part 1 is a single-group, unblinded study Part 2 is a randomized, parallel-group, placebo-controlled, double-blind study.
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Masking Description: Part 1 is unmasked/open label Part 2 is masked with matching placebo
• Primary Purpose: Treatment
• Official Title: A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Inhaled Tobramycin In People With Cystic Fibrosis Chronically Infected With Pseudomonas Aeruginosa
• Actual Study Start Date: January 17, 2024
• Estimated Primary Completion Date: February 2025
• Estimated Study Completion Date: February 2025

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo; Matching placebo, 100mL normal saline	Drug: Placebo; Placebo is normal saline administered as a single IV infusion over approximately 60 minutes.
Experimental: 5 mg/kg CMTX-101; 5mg/kg CMTX-101 in 100mL normal saline	Drug: CMTX-101; CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.
Experimental: 30 mg/kg CMTX-101; 30 mg/kg CMTX-101 in 100mL normal saline	Drug: CMTX-101; CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.
Experimental: 15 mg/kg CMTX-101; 15 mg/kg CMTX-101 in 100mL normal saline	Drug: CMTX-101; CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.

Outcome Measures

Primary Outcome Measures :

1. Number and % of participants experiencing adverse events following a single IV infusion of CMTX-101 [ Time Frame: Day 1 to Day 28 ]
   Primary objective
2. Number and % of participants experiencing serious adverse events following a single IV infusion of CMTX-101 [ Time Frame: Day 1 to Day 28 ]
   Primary objective

Secondary Outcome Measures :

1. Assess the CMax - observed maximum plasma concentration determined by ELISA following a single IV infustion of CMTX-101 [ Time Frame: Day 1 to Day 35 ]
   Secondary objective
2. Assess the TMax - time to reach maximum concentration curve following a single IV infusion of CMTX-101 [ Time Frame: Day 1 to Day 35 ]
   Secondary objective
3. Assess the AUC0-∞ Area under the concentration time curve from zero to infinite time following a single IV infusion of CMTX-101 [ Time Frame: Day 1 to Day 35 ]
   Secondary objective
4. Assess the Terminal phase elimination rate determined by ELISA following a single IV infusion of CMTX-101 [ Time Frame: Day 1 to Day 35 ]
   Secondary objective
5. Assess the Terminal elimination half- determined by ELISA following a single IV infusion of CMTX-101 [ Time Frame: Day 1 to Day 35 ]
   Secondary objective
6. Assess the Apparent total body clearance (CL/F) determined by ELISA following a single IV infusion of CMTX-101 [ Time Frame: Day 1 to Day 35 ]
   Secondary objective
7. Assess the Apparent volume distribution (Vx/F) determined by ELISA following a single IV infustion of CMTX-101 [ Time Frame: Day 1 to Day 35 ]
   Secondary objective
8. Evaluate the immunogenicity of CMTX-101 as measured by anti-drug antibodies (ADA) determined by the electrochemiluminescence assay following a single IV infustion of CMTX-101 [ Time Frame: Day 1 to Day 35 ]
   Secondary objective
9. Assess the apparent reduction in pulmonary P. auriginosa burden as measured by quantitative microbial culture of sputum [ Time Frame: Day 1 to Day 28 ]
   Secondary objective

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Adults ≥18 years of age at the time of screening.
2. Confirmed CF diagnosis based on current CF Foundation (CFF)-sponsored guidelines.
3. For participants on modulator therapy, they must be on a stable dose of TRIKAFTA (ETI) modulator therapy for at least 3 months.
4. Willing and capable of providing induced sputum for evaluation at defined study timepoints.
5. Positive P. aeruginosa growth of ≥104 CFU/gram from a sample of induced sputum at the screening visit.
6. FEV1 ≥50% (Part1) or ≥35% (Part 2) of predicted normal value at screening.

7. Currently receiving inhaled tobramycin alone or CAT therapy. At least one 28-day cycle completed within 8 weeks prior to screening visit.

   • Note: If on CAT therapy, initiation of inhaled tobramycin should begin approximately 2 hours (±1 hour) pre-dose.

8. Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin test during screening and agree to use an effective method of contraception for the duration of the study and for 4 months after the last infusion of study drug. A female participant is considered of childbearing potential unless postmenopausal or surgically sterilized and at least 3 months has passed since sterilization procedure. Female surgical sterilization procedures include tubal ligation, bilateral salpingectomy, hysterectomy, or bilateral oophorectomy. A female participant is considered postmenopausal if she has had spontaneous amenorrhea for at least 2 years with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms).

   • Effective methods of contraception include (a) abstinence, (b) partner vasectomy, (c) intrauterine devices, (d) hormonal implants (such as Implanon), or (e) other hormonal methods (birth control pills, injections, patches, vaginal rings).

9. Male participants with a female partner must use a medically accepted contraceptive regimen during his participation in the study and for 4 months after study drug infusion.

   • Acceptable methods of contraception for male participants include condoms with spermicide, surgical sterilization of the participant (i.e., vasectomy) at least 26 weeks before screening, or sexual abstinence (i.e., refraining from heterosexual intercourse) if that is the preferred and usual lifestyle of the participant.

10. Male participants must agree to abstain from sperm donation through 4 months after study drug administration.
11. Capable of providing informed consent.
12. Capable and willing to complete all study visits and perform all procedures required by the protocol.

Exclusion Criteria:

1. Body mass index (BMI) <14 at screening and baseline.
2. Has a known history or evidence of human immunodeficiency virus (HIV) infection or chronic hepatitis B screening.
3. Tests positive for hepatitis C virus (HCV) RNA at screening.
4. Changes in underlying therapy (e.g., pulmonary massage therapy, bronchodilators, nonsteroidal anti-inflammatory drugs [NSAIDs], antibiotic agents, pancreatic enzyme preparations, nutritional supplements, and DNase) within the 21 days before, and inclusive of, study baseline or anticipated changes to underlying therapy during the study.
5. Pulmonary exacerbation within 28 days of baseline.
6. Requirement for continuous (24 hour/day) oxygen supplementation; periodic use is permitted.
7. Participation in smoking or vaping activity in the last 6 months.
8. History of, or planned, organ transplantation.

9. Elevated liver function tests obtained at screening.

   1. ALT >5 × ULN or AST >5 × ULN, or
   2. Total bilirubin >3 × ULN or Total bilirubin >1.5 × ULN combined with either ALT >3 × ULN or AST >3 × ULN. ULN reflects local laboratory ranges.
10. Greater than 5 ml of hemoptysis on one occasion or >30 mL of hemoptysis in a 24-hour period within 28 days of baseline.
11. Infection with other more pathogenic organisms such as Mycobacterium abscessus or Burkholderia spp., where the investigator feels that the participant either is not or will not remain clinically stable throughout the duration of the study.
12. Acute clinical illness requiring a new (oral, parenteral, or inhaled) antibiotic(s) ≤30 days prior to the baseline visit. Does not include chronic suppressive medications or cyclic dosing medications such as inhaled antibiotics.
13. Women who are pregnant, planning to become pregnant during the study period or for 4 months following last infusion of study drug, or breastfeeding.
14. Active treatment of any mycobacterial or fungal organisms ≤30 days prior to baseline visit. Chronic treatment for suppression of fungal populations is allowable.
15. Anticipated need to change chronic (either inhaled or oral) antibiotic regimens during the study period. Participants must agree to maintain their current chronic antibiotic regimen from the screening visit for the duration of the follow-up period (approximately 30 days).
16. Known allergy to any component of the study drug.
17. Participant with an estimated glomerular filtration rate <60 mL/min/1.73 m2.
18. Any significant finding that, in the opinion of the investigator, would make it unsafe for the participant to participate in this study or would not be in the best interest of the participant.
19. Enrolled in an interventional clinical study within ≤60 days of the baseline visit, or participating in a clinical study while enrolled in this clinical study (inclusive of vaccine studies).
20. Currently or previously enrolled in this study.

Contacts and Locations

Contacts

Contact: Teresa Byrne; 4844677678; tbyrne@clarametyx.com

Contact: Veronica Hall; 6146862689 ext 5; vhall@clarametyx.com

Locations

United States, California

Stanford University; Recruiting

Palo Alto, California, United States, 94304

Contact: Monica Elazar monica8@stanford.edu

Principal Investigator: Carlos Milla, MD

United States, Colorado

National Jewish Health; Recruiting

Denver, Colorado, United States, 80206

Contact: Megan Taylor taylormegan@njhealth.org

Principal Investigator: Jerry Nick, MD

United States, Florida

Central Florida Pulmonary Group, PA; Recruiting

Orlando, Florida, United States, 32803

Contact: Desiree Serr dserr@cfpulmonary.com

Principal Investigator: Francisco Calimano, MD

United States, Idaho

St Luke's Sleep Medicine and Research Center; Recruiting

Boise, Idaho, United States, 83702

Contact: Dixie Durham durhamd@slhs.org

Principal Investigator: Karen Miller, MD

United States, Massachusetts

Boston Children's Hospital; Recruiting

Boston, Massachusetts, United States, 02115

Contact: Monica Ulles monica.ulles@childrens.harvard.edu

Principal Investigator: Ryan Perkins, MD

United States, Michigan

University of Michigan; Recruiting

Ann Arbor, Michigan, United States, 48109

Contact: Dawn Kruse dmkruse@med.umich.edu

Principal Investigator: Lindsay Caverly, MD

United States, New York

New York Medical College; Recruiting

Hawthorne, New York, United States, 10532

Contact: Zachary Messer zachary_messer@nymc.edu

Principal Investigator: John Welter, MD

United States, Ohio

Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center; Recruiting

Cleveland, Ohio, United States, 44106

Contact: Cindy Schaefer cindy.schaefer@uhhospitals.org

Principal Investigator: Alex Gifford, MD

Nationwide Children's Hospital; Recruiting

Columbus, Ohio, United States, 43205

Contact: Terri Johnson terri.johnson@nationwidechildrens.org

Principal Investigator: Karen McCoy, MD

United States, Pennsylvania

PennState Health; Recruiting

Hershey, Pennsylvania, United States, 17003

Contact: Diane Kitch dkitch@pennstatehealth.psu.edu

Principal Investigator: Judie Howrylak, MD

United States, Utah

University of Utah; Recruiting

Salt Lake City, Utah, United States, 84132

Contact: Judy Jensen judy.jensen@hsc.utah.edu

Principal Investigator: Theodore Liou, MD

United States, Washington

Seattle Children's Hospital; Recruiting

Seattle, Washington, United States, 98105

Contact: Ronald Gibson ron.gibson@seattlechildrens.org

Principal Investigator: Ronald Gibson, MD

Sponsors and Collaborators

Clarametyx Biosciences, Inc.

More Information

• Responsible Party: Clarametyx Biosciences, Inc.
• ClinicalTrials.gov Identifier: NCT06159725
• Other Study ID Numbers: CMTX101-P1-CT002
• First Posted: December 7, 2023
• Last Update Posted: May 9, 2024
• Last Verified: February 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Clarametyx Biosciences, Inc.:

Pseudamonas auriginosa

Additional relevant MeSH terms:

Persistent Infection; Cystic Fibrosis; Fibrosis; Pathologic Processes; Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Infant, Newborn, Diseases; Infections; Disease Attributes